NEW YORK–(Business Wire)–
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biotechnology company
engaged in the research, development, manufacture, licensing and marketing of
innovative health care products, platforms and services based on molecular and
cellular technologies, announced today that Barry Weiner, President, and David
Goldberg, Vice President, Corporate Development, will be presenting at the 9th
annual Needham Healthcare Conference on Thursday, June 10th, 2010 at 3:20 PM at
The New York Palace Hotel in New York, N.Y.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and
biotechnology company focused on harnessing biological process to develop
research tools, diagnostics and therapeutics, and serves as a provider of test
services, including exotic tests, to the medical community. Since our founding
in 1976, our strategic focus has been on the development of enabling
technologies in the life sciences field. Enzo Life Sciences develops, produces
and markets proprietary labeling and detection products for gene sequencing,
genetic analysis and immunological research, among others. Its catalog of over
40,000 products serve the molecular biology, drug discovery and pathology
research markets worldwide. Enzo Clinical Labs provides laboratory services for
a growing roster of physicians in the New York Metropolitan area, as well as
parts of New Jersey and Pennsylvania. Its tests include, in addition to routine
tests, capabilities for detecting molecular infection disease, molecular
oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides
clinical diagnostic services that allow Enzo to capitalize on its extensive
advanced molecular and cytogenetic capabilities and the broader trends in
predictive and personalized diagnostics. Enzo Therapeutics is a
biopharmaceutical venture that has developed multiple novel approaches in the
areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has
focused its efforts on developing treatment regimens for diseases and conditions
for which current treatment options are ineffective, costly, and/or cause
unwanted side effects. In the course of the company`s research and development
activities, Enzo has developed a substantial portfolio of intellectual property
assets, with 249 issued patents worldwide and over 200 pending patent
applications.
Except for historical information, the matters discussed in this news release
may be considered “forward-looking” statements within the meaning of Section 27A
of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its management.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and uncertainties
that could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of developments
occurring after the date of this press release.
For Enzo Biochem, Inc.
Steven Anreder, 212-532-3232
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
Copyright Business Wire 2010